A post-marketing database surveillance to investigate the risk of diagnosed myelosuppression events in MRSA patients treated with tedizolid or linezolid in Japan (MK-1986-045)

14/01/2026
14/01/2026
EU PAS number:
EUPAS1000000896
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

E_MK-1986-045_post-marketing database study_Myelosuppression_protocol_final-redaction.pdf

English (1.73 MB - PDF) View document
Study results
Study report
Other information